These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26728136)

  • 1. PEO-PPO-PEO/Poly(DL-lactide-co-caprolactone) Nanoparticles as Carriers for SN-38: Design, Optimization and Nano-Bio Interface Interactions.
    Koliqi R; Dimchevska S; Geskovski N; Petruševski G; Chacorovska M; Pejova B; Hristov DR; Ugarkovic S; Goracinova K
    Curr Drug Deliv; 2016; 13(3):339-52. PubMed ID: 26728136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy assessment of self-assembled PLGA-PEG-PLGA nanoparticles: Correlation of nano-bio interface interactions, biodistribution, internalization and gene expression studies.
    Dimchevska S; Geskovski N; Koliqi R; Matevska-Geskovska N; Gomez Vallejo V; Szczupak B; Sebastian ES; Llop J; Hristov DR; Monopoli MP; Petruševski G; Ugarkovic S; Dimovski A; Goracinova K
    Int J Pharm; 2017 Nov; 533(2):389-401. PubMed ID: 28552798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Definition of formulation design space, in vitro bioactivity and in vivo biodistribution for hydrophilic drug loaded PLGA/PEO-PPO-PEO nanoparticles using OFAT experiments.
    Simonoska Crcarevska M; Geskovski N; Calis S; Dimchevska S; Kuzmanovska S; Petruševski G; Kajdžanoska M; Ugarkovic S; Goracinova K
    Eur J Pharm Sci; 2013 Apr; 49(1):65-80. PubMed ID: 23439240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of Design of Expert software for evaluating the influence of formulation variables on the encapsulation efficacy, drug content and particle size of PEO-PPO-PEO/Poly (DL-lactide-co-caprolactone) nanoparticles as carriers for SN-38.
    Koliqi R; Breznica P; Daka A; Koshi B
    Med Pharm Rep; 2021 Oct; 94(4):483-497. PubMed ID: 36105496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SN-38 loading capacity of hydrophobic polymer blend nanoparticles: formulation, optimization and efficacy evaluation.
    Dimchevska S; Geskovski N; Petruševski G; Chacorovska M; Popeski-Dimovski R; Ugarkovic S; Goracinova K
    Drug Dev Ind Pharm; 2017 Mar; 43(3):502-510. PubMed ID: 27910713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2).
    Guo S; Zhang X; Gan L; Zhu C; Gan Y
    J Pharm Pharmacol; 2010 Aug; 62(8):973-84. PubMed ID: 20663031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preparation and characterization of irinotecan hydrochloride loaded PEO-PPO-PEO micelles and its mechanism of decreasing drug intestinal toxicity].
    Zhang XX; Guo SY; Li FF; Gan Y
    Yao Xue Xue Bao; 2012 Nov; 47(11):1534-40. PubMed ID: 23387089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and characterization of poly lactide-co-glycolide nanoparticles of SN-38.
    Ebrahimnejad P; Dinarvand R; Sajadi SA; Atyabi F; Ramezani F; Jaafari MR
    PDA J Pharm Sci Technol; 2009; 63(6):512-20. PubMed ID: 20169857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization, blood profile and biodistribution properties of surface modified PLGA nanoparticles of SN-38.
    Ebrahimnejad P; Dinarvand R; Jafari MR; Tabasi SA; Atyabi F
    Int J Pharm; 2011 Mar; 406(1-2):122-7. PubMed ID: 21185365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan.
    Sepehri N; Rouhani H; Tavassolian F; Montazeri H; Khoshayand MR; Ghahremani MH; Ostad SN; Atyabi F; Dinarvand R
    Int J Pharm; 2014 Aug; 471(1-2):485-97. PubMed ID: 24879937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and in vitro characterization of SN-38-loaded, self-forming polymeric depots as an injectable drug delivery system.
    Manaspon C; Hongeng S; Boongird A; Nasongkla N
    J Pharm Sci; 2012 Oct; 101(10):3708-17. PubMed ID: 22778058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-tocopheryl polyethylene glycol succinate-emulsified poly(lactic-co-glycolic acid) nanoparticles for reversal of multidrug resistance in vitro.
    Wang Y; Guo M; Lu Y; Ding LY; Ron WT; Liu YQ; Song FF; Yu SQ
    Nanotechnology; 2012 Dec; 23(49):495103. PubMed ID: 23149859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Particle characteristics and biodistribution of camptothecin-loaded PLA/(PEG-PPG-PEG) nanoparticles.
    Kunii R; Onishi H; Ueki K; Koyama K; Machida Y
    Drug Deliv; 2008 Jan; 15(1):3-10. PubMed ID: 18197517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles.
    Hong M; Zhu S; Jiang Y; Tang G; Sun C; Fang C; Shi B; Pei Y
    J Control Release; 2010 Jan; 141(1):22-9. PubMed ID: 19735683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of mPEG-PCL and mPEG-PLGA on encapsulation efficiency and drug-loading of SN-38 NPs.
    Gan M; Zhang W; Wei S; Dang H
    Artif Cells Nanomed Biotechnol; 2017 Mar; 45(2):389-397. PubMed ID: 27043776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel drug-polyethylene glycol liquid compound method to prepare 10-hydroxycamptothecin loaded human serum albumin nanoparticle.
    Yang Z; Gong W; Wang Z; Li B; Li M; Xie X; Zhang H; Yang Y; Li Z; Li Y; Yu F; Mei X
    Int J Pharm; 2015 Jul; 490(1-2):412-28. PubMed ID: 26027489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain delivery of camptothecin by means of solid lipid nanoparticles: formulation design, in vitro and in vivo studies.
    Martins S; Tho I; Reimold I; Fricker G; Souto E; Ferreira D; Brandl M
    Int J Pharm; 2012 Dec; 439(1-2):49-62. PubMed ID: 23046667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer.
    Shenoy DB; Amiji MM
    Int J Pharm; 2005 Apr; 293(1-2):261-70. PubMed ID: 15778064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a novel biocompatible poly(ethylene glycol)-block-poly(γ-cholesterol-L-glutamate) as hydrophobic drug carrier.
    Ma Q; Li B; Yu Y; Zhang Y; Wu Y; Ren W; Zheng Y; He J; Xie Y; Song X; He G
    Int J Pharm; 2013 Mar; 445(1-2):88-92. PubMed ID: 23376505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles.
    Liu Q; Li R; Zhu Z; Qian X; Guan W; Yu L; Yang M; Jiang X; Liu B
    Int J Pharm; 2012 Jul; 430(1-2):350-8. PubMed ID: 22525076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.